Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Post by Dibah42on Nov 12, 2013 9:34am
241 Views
Post# 21896877

HOLX takes $1.1b impairment

HOLX takes $1.1b impairment
Stock tanks in after-close.  Looks like Jack Cumming who was recalled from retirement to fix things has rammed all the bad news into this Q.  The GPRO side was the main saviour growing at 14% while the breast health grew at 1%.  And yet one has to wonder if they overpaid for the GPRO acquisition.
The company keeps mouthing inanities  "Womens' health is the very reason for our existence".  "Our business is saving lives"  (mens'  lives???)
Of course there is no mention of Progensa although most of the clean-up/savings  is supposed to be on the Diagnostic side.
Does this present an opportunity for Bordeleau?  Remains to be seen.  Quebec City is silent.
<< Previous
Bullboard Posts
Next >>